DSM Capital Partners LLC Acquires 1,098,243 Shares of DexCom, Inc. $DXCM

DSM Capital Partners LLC increased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 76.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,533,539 shares of the medical device company’s stock after acquiring an additional 1,098,243 shares during the quarter. DexCom comprises 2.4% of DSM Capital Partners LLC’s portfolio, making the stock its 13th biggest holding. DSM Capital Partners LLC owned 0.65% of DexCom worth $170,482,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Andra AP fonden bought a new position in DexCom during the second quarter worth $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom during the 2nd quarter worth about $26,000. SJS Investment Consulting Inc. lifted its stake in shares of DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of DexCom during the 3rd quarter worth about $29,000. Finally, Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the 2nd quarter valued at about $45,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on DXCM. Canaccord Genuity Group set a $99.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Wall Street Zen lowered DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 16th. Sanford C. Bernstein restated an “outperform” rating and issued a $84.00 price target on shares of DexCom in a research note on Monday, November 3rd. TD Cowen decreased their price objective on DexCom from $100.00 to $84.00 and set a “buy” rating on the stock in a report on Friday, October 31st. Finally, Wells Fargo & Company set a $93.00 price objective on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

DexCom Stock Performance

NASDAQ:DXCM opened at $69.89 on Wednesday. The company has a market cap of $27.26 billion, a price-to-earnings ratio of 38.83, a PEG ratio of 1.22 and a beta of 1.48. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.38 and a current ratio of 1.56. The stock has a fifty day moving average price of $63.69 and a 200-day moving average price of $72.33.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter last year, the business earned $0.45 earnings per share. DexCom’s revenue was up 21.6% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach purchased 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The shares were acquired at an average price of $55.04 per share, for a total transaction of $1,001,728.00. Following the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $59.05, for a total transaction of $171,599.30. Following the transaction, the director owned 35,088 shares of the company’s stock, valued at approximately $2,071,946.40. This represents a 7.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 7,866 shares of company stock valued at $448,177. Company insiders own 0.32% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.